We are live on ! Find out more
BIB icon

ProShares Ultra NASDAQ Biotechnology
BIB

35 hedge funds and large institutions have $28.7M invested in ProShares Ultra NASDAQ Biotechnology in 2016 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 7

37% more capital invested

Capital invested by funds: $21M → $28.7M (+$7.76M)

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

13% more funds holding

Funds holding: 31 → 35 (+4)

1% more call options, than puts

Call options by funds: $17.4M | Put options by funds: $17.3M

Holders
35
Holders Change
+4
Holders Change %
+12.9%
% of All Funds
0.93%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
12
Increased
10
Reduced
8
Closed
7
Calls
$17.4M
Puts
$17.3M
Net Calls
+$122K
Net Calls Change
-$4.59M

Top Buyers

Rank Fund Capital Flow
1
OPPM
Opus Point Partners Management
New York
+$4.04M
2
CIC
Chase Investment Counsel
Virginia
+$2.2M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.77M
4
BA
BKS Advisors
Michigan
+$1.76M
5
BG
Bellevue Group
Switzerland
+$1.19M

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$2.79M
2
VF
Virtu Financial
New York
-$2.24M
3
Citadel Advisors
Citadel Advisors
Florida
-$1.61M
4
RIA
RPG Investment Advisory
California
-$850K
5
Jane Street
Jane Street
New York
-$663K
Name Holding Trade Value Shares
Change 		Change in
Stake
EWM
26
Edge Wealth Management
New York
$24K +$23.8K +500 New
LTFS
27
Ladenburg Thalmann Financial Services
Florida
$15K – – –
CG
28
Cutler Group
California
$13K -$72.7K -1,530 -85%
AG
29
Advisor Group
Arizona
$12K -$8.31K -175 -42%
GWM
30
Geneos Wealth Management
Colorado
$8K +$4.75K +100 +120%
MFS
31
MSI Financial Services
Massachusetts
$5K – – –
FTUS
32
Flow Traders U.S.
New York
$5K +$4.75K +100 New
Walleye Trading
33
Walleye Trading
New York
$5K +$4.75K +100 New
TCM
34
Tradewinds Capital Management
Washington
$2K +$1.9K +40 New
VF
35
Virtu Financial
New York
– -$2.24M -57,736 Closed
Citadel Advisors
36
Citadel Advisors
Florida
– -$1.61M -33,894 Closed
CT
37
CMT Trading
Illinois
– -$571K -14,707 Closed
HF
38
HRT Financial
New York
– -$376K -9,694 Closed
TSS
39
Two Sigma Securities
New York
– -$208K -5,365 Closed
UBS Group
40
UBS Group
Switzerland
– -$77K -1,991 Closed
PCM
41
Prelude Capital Management
New York
– -$41K -1,055 Closed
1
2

BIB Hedge Fund Activity: Q3 2016 in Review

35 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q3 2016, worth a combined $28.7M — up 37% from $21M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new BIB positions and 7 closed out — a net gain of 5 holders — while 10 added to existing stakes and 8 trimmed.

The largest buyer was Opus Point Partners Management, opening a new position worth an estimated $4.04M. The largest seller was Tower Research Capital (TRC), cutting an estimated $2.79M.

  • 35 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q3 2016, up from 31 in Q2 2016.
  • Funds reported $28.7M of ProShares Ultra NASDAQ Biotechnology stock for Q3 2016, up 37% quarter-over-quarter.
  • 12 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q3 2016 and 7 closed out, a net change of +5 holders.
  • The largest ProShares Ultra NASDAQ Biotechnology buyer in Q3 2016 was Opus Point Partners Management, an estimated $4.04M added.
  • The largest ProShares Ultra NASDAQ Biotechnology seller in Q3 2016 was Tower Research Capital (TRC), an estimated $2.79M sold.

Based on aggregated 13F filings for Q3 2016.